US 11,833,167 B2
Nicotinyl riboside compounds and their uses
Gangadhara Ganapati, Palo Alto, CA (US); and Atignal Shankara Rao Arvind, Bangalore (IN)
Assigned to MitoPower LLC, Palo Alto, CA (US)
Appl. No. 17/415,428
Filed by MitoPower, LLC, Palo Alto, CA (US)
PCT Filed Dec. 12, 2019, PCT No. PCT/US2019/066064
§ 371(c)(1), (2) Date Jun. 17, 2021,
PCT Pub. No. WO2020/131578, PCT Pub. Date Jun. 25, 2020.
Claims priority of provisional application 62/780,559, filed on Dec. 17, 2018.
Prior Publication US 2022/0062314 A1, Mar. 3, 2022
Int. Cl. A61K 31/70 (2006.01); A01N 43/04 (2006.01); A61K 31/706 (2006.01); A61P 3/10 (2006.01); A61K 31/502 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/706 (2013.01) [A61K 31/502 (2013.01); A61K 45/06 (2013.01); A61P 3/10 (2018.01)] 7 Claims
 
1. A method of increasing cytoprotection in a cell type or tissue at risk of DNA damage in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (V) or Formula (VI):

OG Complex Work Unit Chemistry
or pharmaceutically acceptable salts and a therapeutically effective amount of olaparib or pharmaceutically acceptable salts thereof, wherein:
Y and Z are —OH or —NH2;
X− is fluoride, chloride, bromide, iodide, nitrate, sulfate, sulfite, phosphate, bicarbonate, carbonate, thiocyanate, formate, acetate, trifluoroacetate, glycolate, lactate, gluconate, ascorbate, benzoate, oxalate, malonate, succinate, citrate, methanesulfonate, ethanesulfonate, propanesulfonate, benzenesulfonate, p-toluenesulfonate or trifluoromethanesulfonate; and the therapeutically effective amount of olaparib is not more than about 10% of the therapeutically effective amount of olaparib used in chemotherapy.